Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
1990-7-23
|
pubmed:abstractText |
Previous studies have suggested that overexpression of HER-2/neu oncogene occurs in 15-40% of breast cancers and that overexpression is associated with poor prognosis. In the present report, we have used an immunohistochemical technique involving a monoclonal antibody specifically reactive with the external domain of HER-2/neu to study expression of HER-2/neu in frozen sections of normal ovary and advanced epithelial ovarian cancer. The intensity of staining for HER-2neu was always moderate or less (0-2+) in normal ovarian epithelium. Among 73 ovarian cancers, 50 (68%) had staining similar to that for normal ovarian epithelium (0-2+) while 23 (32%) stained heavily (3+). Survival of the 23 patients with high HER-2/neu expression (median, 15.7 months) was significantly worse (P = 0.001) than that of the 50 patients (median, 32.8 months) with normal HER-2/neu expression. In addition, patients whose tumors had high HER-2/neu expression were significantly less likely to have a complete response to primary therapy (P less than 0.05) or have a negative second-look laparotomy when serum CA 125 levels were normal preoperatively (P less than 0.05). These findings suggest that HER-2/neu deserves further evaluation as a prognostic marker in epithelial ovarian cancer.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
4087-91
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:1972347-Female,
pubmed-meshheading:1972347-Humans,
pubmed-meshheading:1972347-Neoplasm Recurrence, Local,
pubmed-meshheading:1972347-Ovarian Neoplasms,
pubmed-meshheading:1972347-Probability,
pubmed-meshheading:1972347-Prognosis,
pubmed-meshheading:1972347-Proto-Oncogene Proteins,
pubmed-meshheading:1972347-Receptor, erbB-2,
pubmed-meshheading:1972347-Reoperation
|
pubmed:year |
1990
|
pubmed:articleTitle |
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|